Market Closed -
Nasdaq
04:30:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
2
USD
|
-19.68%
|
|
+32.45%
|
-25.09%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
11.52
|
37.99
|
38.8
|
8.364
|
2.722
|
2.637
|
-
|
-
|
Enterprise Value (EV)
1 |
11.52
|
37.99
|
38.8
|
8.364
|
2.722
|
2.637
|
2.637
|
2.637
|
P/E ratio
|
-1.34
x
|
-2.28
x
|
-1.82
x
|
-0.35
x
|
-0.1
x
|
-0.21
x
|
-0.48
x
|
0.56
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
-
|
-
|
6.48
x
|
-
|
-
|
0.05
x
|
EV / Revenue
|
-
|
-
|
-
|
-
|
6.48
x
|
-
|
-
|
0.05
x
|
EV / EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
57.3
|
324
|
665
|
836
|
1,019
|
1,318
|
-
|
-
|
Reference price
2 |
201.0
|
117.1
|
58.35
|
10.00
|
2.670
|
2.000
|
2.000
|
2.000
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
0.42
|
-
|
-
|
55.99
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-9.682
|
-10.64
|
-22.94
|
-27.66
|
-25.45
|
-21.7
|
-29.38
|
24.03
|
Operating Margin
|
-
|
-
|
-
|
-
|
-6,060.24%
|
-
|
-
|
42.91%
|
Earnings before Tax (EBT)
1 |
-9.126
|
-9.681
|
-22.73
|
-25.92
|
-25.55
|
-26.94
|
-28.78
|
25.43
|
Net income
1 |
-8.03
|
-12.4
|
-19.09
|
-21.4
|
-22.76
|
-24.94
|
-26.88
|
27.33
|
Net margin
|
-
|
-
|
-
|
-
|
-5,418.1%
|
-
|
-
|
48.8%
|
EPS
2 |
-150.0
|
-51.30
|
-32.10
|
-28.50
|
-26.75
|
-9.435
|
-4.130
|
3.550
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
0.373
|
0.016
|
0.031
|
-
|
-
|
-
|
-
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-5.998
|
-6.534
|
-6.559
|
-5.785
|
-6.467
|
-8.845
|
-7.319
|
-5.929
|
-6.845
|
-5.36
|
-5.574
|
-5.405
|
-5.361
|
-5.361
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,589.54%
|
-42,781.25%
|
-17,290.32%
|
-
|
-
|
-
|
-
|
Earnings before Tax (EBT)
1 |
-5.985
|
-6.491
|
-5.246
|
-5.559
|
-6.11
|
-9
|
-7.124
|
-6.034
|
-6.699
|
-5.693
|
-6.561
|
-6.677
|
-6.794
|
-6.914
|
Net income
1 |
-5.037
|
-5.344
|
-4.158
|
-4.625
|
-5.146
|
-7.469
|
-5.854
|
-5.498
|
-6.147
|
-5.321
|
-6.061
|
-6.177
|
-6.294
|
-6.414
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-1,473.99%
|
-38,418.75%
|
-17,164.52%
|
-
|
-
|
-
|
-
|
EPS
2 |
-8.100
|
-8.100
|
-6.300
|
-6.900
|
-6.300
|
-9.000
|
-7.050
|
-6.600
|
-7.350
|
-6.230
|
-4.745
|
-2.395
|
-2.110
|
-1.810
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/28/22
|
5/11/22
|
8/10/22
|
11/9/22
|
3/6/23
|
5/11/23
|
8/9/23
|
11/13/23
|
3/19/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex / Sales
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/26/20
|
2/25/21
|
3/28/22
|
3/6/23
|
3/19/24
|
-
|
-
|
-
|
Average target price
11
USD Spread / Average Target +450.00% Consensus |
1st Jan change
|
Capi.
|
---|
| -25.09% | 2.64M | | +8.96% | 105B | | -1.43% | 104B | | +5.47% | 22.94B | | -12.15% | 22.34B | | -6.08% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|